A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: Etentamig
DRUG: Pomalidomide
DRUG: Daratumumab
DRUG: Dexamethasone
DRUG: Carfilzomib
DRUG: Teclistamab

Sponsor

AbbVie